相关实验视频

Updated: Jun 18, 2025

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

在一般化肌痛性肌痛症患者中,使用eculizumab和efgartigimod的现实经验

Chiara Pane¹, Vincenzo Di Stefano², Nunzia Cuomo¹

¹Neuroscience, Reproductive and Odontostomatological Sciences (NSRO) Department, Federico II University, Naples, Italy.

Journal of neurology

|July 30, 2024

概括

埃奎利祖马布和efgartigimod都用于治疗一般化骨髓灰质炎 (gMG). 埃奎利祖马布在QMG得分和类固醇减少方面表现出更大的改善,而efgartigimod在抗体阴性患者中表现出更大的疗效.

科学领域:

神经学神经学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

埃奎利祖马布 (补充活性抗体) 和efgartigimod (新生儿Fc受体阻断剂) 已被批准用于一般化骨髓灰质炎 (gMG).
关于这些治疗方法的比较疗效的现实世界临床数据有限.

研究的目的:

在现实环境中比较gMG患者对eculizumab和efgartigimod的临床反应.
通过验证的临床量表来评估治疗疗效,并评估类固醇节约效应.

主要方法:

对63名gMG患者 (32名eculizumab,31名efgartigimod) 的回顾性分析.
采集的临床数据使用了Myasthenia Gravis-日常生活活动 (MG-ADL) 和量化Myasthenia Gravis (QMG) 尺度.
对efgartigimod亚组的分析包括抗乙胆受体抗体阳性 (AChR-Ab+) 和阴性 (AChR-Ab-) 患者.

主要成果:

这两种治疗方法在MG-ADL尺度上表现出相似的疗效 (p=0.237).
与efgartigimod (OR 1.373; p=0.016) 相比,eculizumab表现出优异的QMG得分降低 (p=0.003) 和更高的临床响应可能性.
与efgartigimod相比,eculizumab表现出明显更大的类固醇节约效应 (p=0.001) 和更快的普得尼松降低.

结论:

在临床实践中,eculizumab和efgartigimod有效地减少了gMG患者的残疾.
埃奎利祖马布在QMG反应和降低类固醇方面具有优势.
在ACHR-Ab-患者中,efgartigimod提供了灵活性和有效性,具有循环管理的潜力,不需要接种疫苗.

关键词:

具有创新性的创新.MG-ADL MG-ADL 的意思是什么意思观测性观测性观测性在QMG中使用QMG.现实世界的证据.血清阴性血清阴性

更多相关视频

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Antigenic Liposomes for Generation of Disease-specific Antibodies

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

相关概念视频

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Disorders of the Skeletal Muscle

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...